Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.78 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL1711073 | 1.00 | AKR1B1 (0.78) | AKR1B1OR51E2TDP1LMNAALDH1A1 | |
| Acetone SCHEMBL28376337 | 1.00 | AKR1B1 (0.78) | AKR1B1OR51E2TDP1LMNAALDH1A1 | |
| Acetone SCHEMBL9466071 | 1.00 | AKR1B1 (0.78) | AKR1B1OR51E2TDP1LMNAALDH1A1 | |
| Acetone SCHEMBL2871076 | 1.00 | AKR1B1 (0.78) | AKR1B1OR51E2TDP1LMNAALDH1A1 | |
| Acetone SCHEMBL27957990 | 0.93 | AKR1B1 (0.67) | AKR1B1PAX8 | |
| SCHEMBL8440817 | 0.90 | AKR1B1 (0.70) | AKR1B1OR51E2TDP1ALDH1A1PAX8 | |
| Mannitol SCHEMBL10506495 | 0.89 | AKR1B1 (0.61) | AKR1B1TDP1LMNAPAX8 | |
| SCHEMBL19505 | 0.88 | — | — | |
| SCHEMBL2121317 | 0.88 | — | — | |
| SCHEMBL22045 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801518-B | A kind of synthetic method of (S) -1-Boc-3- hydroxy piperidine | 重庆博腾制药科技股份有限公司 | 2018-11-27 | — | — | CN | claimed |
| CN-105801518-A | (S)-1-Boc-3-hydroxypiperidine synthesis method | 重庆博腾制药科技股份有限公司 | 2016-07-27 | — | — | CN | claimed |
| CN-104829584-A | Synthesis method of (R)-glyceraldehyde acetonide compound | JIANGSU FURUI BIOPHARMACEUTICAL CO LTD | 2015-08-12 | — | — | CN | claimed |
| CN-118272334-A | Carbonyl reductase mutant and application thereof in synthesis of (R) -N-Boc-3-hydroxy piperidine | 西南大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-108289931-B | 4' -substituted nucleoside reverse transcriptase inhibitors and preparation thereof | 默沙东公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-05-27 | — | — | US | disclosed |
| US-11008358-B2 | Synthesis of desosamines | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-18 | — | — | US | disclosed |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3352781-B1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-109641930-B | Preparation method of 2-fluoro-2-methyl deoxynucleoside serving as sofosbuvir intermediate | 正大天晴药业集团股份有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-05 | — | — | US | disclosed |
| EP-0506235-A1 | Glyceraldehyde-3-pentanide and process for producing same | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| US-5051506-A | Compounds for electrooptical displays | DISPLAYTECH, INC. (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0219505-B1 | STEREOSELECTIVE PROCESS AND CHIRAL INTERMEDIATES FOR ARYLOXYDROPANOLAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-01 | — | — | EP | disclosed |
| EP-0219505-A1 | STEREOSELECTIVE PROCESS AND CHIRAL INTERMEDIATES FOR ARYLOXYDROPANOLAMINES. | SMITH KLINE FRENCH LAB (GB) | 1987-04-29 | — | — | EP | disclosed |
| US-4652563-A | PYRIDAZINONES SUBSTITUTED WITH CYCLOPROPYLMETHOXYETHYL GROUP | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1987-03-24 | — | — | US | disclosed |
| WO-1986006368-A1 | STEREOSELECTIVE PROCESS AND CHIRAL INTERMEDIATES FOR ARYLOXYDROPANOLAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-11-06 | — | — | WO | disclosed |
| EP-0168921-A2 | Chemical compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-01-22 | — | — | EP | disclosed |
| US-4413142-A | MULTISTAGE, D-MANNITOL, KETONE | ANIC S.P.A. (IT) | 1983-11-01 | — | — | US | disclosed |
| EP-0060595-A2 | Method for preparing L-carnitine | ANIC S.p.A. (IT) | 1982-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, SAMHD1, DUT | AKR1B1 211/4885OR51E2 4203/4885TDP1 310/4885 |
| US-11008358-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | AKR1B1 129/4885OR51E2 4467/4885TDP1 2664/4885 |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | AKR1B1 129/4885OR51E2 4467/4885TDP1 2664/4885 |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | DUT, HPRT1, SAMHD1 | AKR1B1 241/4885OR51E2 4204/4885TDP1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.